The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Open accessPublished version of a preprint
Abstract
Immune checkpoint blockade, exemplified by antibodies targeting the PD-1 receptor, can induce durable tumor regressions in some patients. To enhance the efficacy of existing immunotherapies, we screened for small molecules capable of increasing the activity of T cells suppressed by PD-1. Here, we show that short-term exposure to small-molecule inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) significantly enhances T-cell activation, contributing to antitumor effects in vivo, due in part to the derepression of NFAT family proteins and their target genes, critical regulators of T-cell function. Although CDK4/6 inhibitors decrease T-cell proliferation, they increase tumor infiltration and activation of effector T cells. Moreover, CDK4/6 inhibition augments the response to PD-1 blockade in a novel ex vivo organotypic tumor spheroid culture system and in multiple in vivo murine syngeneic models, thereby providing a rationale for combining CDK4/6 inhibitors and immunotherapies. Significance: Our results define previously unrecognized immunomodulatory functions of CDK4/6 and suggest that combining CDK4/6 inhibitors with immune checkpoint blockade may increase treatment efficacy in patients. Furthermore, our study highlights the critical importance of identifying complementary strategies to improve the efficacy of immunotherapy for patients with cancer. Cancer Discov; 8(2); 216–33. ©2017 AACR. See related commentary by Balko and Sosman, p. 143. See related article by Jenkins et al., p. 196. This article is highlighted in the In This Issue feature, p. 127
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“cyclin-dependent kinase inhibitors 4 and 6 (CDK4/6) facilitate T cell activation, resulting in a higher number of tumour-infiltrating T cells in PDOs, cultivated over several days in a microfluidic 3D chip setup.”
From Human disease models in drug development (2023) · cites this paper as [129]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“CDK4/6 inhibition also showed high in vitro and in vivo activity and synergy with anti-PD-1 blocking antibodies129.”
From Human disease models in drug development (2023) · cites this paper as [129]
In the citing paper
“activation of effector T (TEFF) cells upon nuclear factor of activated T cells 1 (NFATC1, best known as NFAT) signaling and interleukin-2 (IL2) secretion (Deng et al., 2018)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Deng et al., 2018
In the citing paper
“CDK4/6 inhibition is also able to stimulate PD-1 expressing T-cells in vitro and enhance T cell infiltration (Deng et al., 2017).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Deng et al., 2017
In the citing paper
“This enhancement is driven at least in part by CDK6-induced phosphorylation of NFAT4.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Deng et al., 2017
In the citing paper
“Combining palbociclib with a PD-1 blockade enhanced tumor regression and improved overall survival in mouse xenograft models of colon adenocarcinoma (Deng et al., 2017; Zhang et al., 2018).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Deng et al., 2017
In the citing paper
“CDK4/6 inhibitors improved the efficacy of α-PD-1 in murine models by enhancing lymphocyte infiltration and TIL activities [245–248].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [248]
In the citing paper
“We also recently demonstrated that CDK6, but not CDK4, phosphorylates NFAT family transcription factors to promote T cell activation and enhance the anti-tumor immune response[7].”
From Development of dual and selective degraders of cyclin-dependent kinases 4 and 6 (2019) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 12×
“The digested NFATc3 and His-GB1 were separated and further purified using size exclusion chromatography (GE Healthcare Life Sciences “Superdex 75 10/300 GL”).”
BackgroundInfluentialNear-optimal probabilistic RNA-seq quantification
Bray, N. L., Pimentel, H., Melsted, P., & Pachter, L. (2016) · Nature Biotechnology · doi:10.1038/nbt.3519 · Cited by 9,723 · cited 11×
“The digested NFATc3 and His-GB1 were separated and further purified using size exclusion chromatography (GE Healthcare Life Sciences “Superdex 75 10/300 GL”).”
BackgroundMethodInfluentialNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 11×
“The digested NFATc3 and His-GB1 were separated and further purified using size exclusion chromatography (GE Healthcare Life Sciences “Superdex 75 10/300 GL”).”
BackgroundInfluentialMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · cited 11×
“The digested NFATc3 and His-GB1 were separated and further purified using size exclusion chromatography (GE Healthcare Life Sciences “Superdex 75 10/300 GL”).”
BackgroundInfluentialTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025 · cited 3×
“The discovery of immune checkpoint receptors, such as CTLA-4 and PD-1 (5-9), that repress the activity of anti-tumor T cells, led to the development of blocking antibodies directed against these co-inhibitory receptors or their ligands, including ipilimumab (anti-CTLA-4), pembrolizumab (anti-PD-1), nivolumab (anti-PD1…”
BackgroundNeoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · cited 11×
“As Kras mutant GEMMs are not responsive to checkpoint blockade (3,44), in part due to a low levels of somatic mutations (45), we utilized the murine syngeneic colon adenocarcinoma model MC38.”
BackgroundMethodInfluential
Cited by
Sorted by citations
Items 601–700 of 776
Shi, A., Kasumova, G. G., Michaud, W. A., Cintolo-Gonzalez, J., Martínez, M. D., Ohmura, J. F., Mehta, A., Chien, I., Frederick, D. T., Cohen, S., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/809699 · Cited by 2
Self-citationSun, L., Yang, H., & Mao, Y. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.11.76 · Cited by 2
“Additionally, the TILs in these models exhibited responses to tumor immunotherapy without immune specificity (13).”
BackgroundTatárová, Z., Blumberg, D. C., Korkola, J. E., Heiser, L. M., Muschler, J. L., Schedin, P. J., Ahn, S. W., Mills, G. B., Coussens, L. M., Jonas, O. H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.01.458631 · Cited by 2
Targeting CDKs with Other Chemotherapeutic Drugs: A Combinatorial Approach
Mir, M. A., & Mir, U. Y. (2023) · Springer eBooks · doi:10.1007/978-981-19-8911-7_13 · Cited by 1
Chen, H., Yan, J., Liu, Z., Ge, X., Sun, X., & Xia, X. (2025) · Current Oncology · doi:10.3390/curroncol32040189 · Cited by 1
Tiburcio, P. D. B., Desai, K. K., Warne, A., Nabbi, A., Zhou, S., Reiff, S. D., Campbell, M. E., Amatruda, J. F., & Chen, K. S.-M. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31852 · Cited by 1
Wu, Y., Xu, Z., Kou, Z., Ye, Q., Chen, L., & Gou, B. (2025) · Scientific Reports · doi:10.1038/s41598-025-11043-5 · Cited by 1
“It has been reported that CDK4/6 inhibitors may trigger antitumor immunity in solid tumors 34–39 and in vivo experiments verified synergistic effects of CDK4/6 inhibition with programmed cell death 1 (PD-1) blockade, which lead to elevated tumor regression and better overall survival rates 34,39,40…”
Saleem, W., Zaidi, S. U. S., Rizwan, S., Naviwala, M. S. S., Ahmed, F., Zehra, N., Zaki, A., & Rashid, Y. A. (2025) · Indus journal of bioscience research. · doi:10.70749/ijbr.v3i7.1877 · Cited by 1
Lu, S., Zhu, W.-T., Song, S.-S., Bao, X., Yu, T. Y., Zhang, Y., Miao, Z., & He, J. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.112051 · Cited by 1
Self-citationLu, Y., Chen, Y., Pan, X., Ma, W., Liu, N., Yang, L., Dong, X., Guo, H., Li, D., & Gan, W. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01125-x · Cited by 1
“Researches have proved that CDK4/6 inhibitors can enhance T-cell activation and upregulate PDL1 on the tumor cell surface [39], and the combination administration of CDK4/6 inhibi - tors with anti-PD-1/PDL1 had entered phase II clinical trials for many tumors, such as breast cancer, non-small cell…”
Tang, Z., Huang, T., & Yang, T.-L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311596 · Cited by 3
“Clinical trials show severe lymphopenia and impaired T cell function [160], with increased risks of interstitial lung disease and pneumonitis, including fatal cases [161].”
Vitiligo associated with ribociclib therapy: a rare case report
Wang, Z., Bai, Y., Wu, R., Liu, Y., Dong, C., & Chen, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1669407 · Cited by 1
“Although CDK4/6 inhibitors demonstrate inhibitory effects on T cell proliferation in vitro , they promote effector T cell activation and tumor tissue in fi ltration within the tumor microenvironment (20).”
Yu, Y., Li, Y., Wang, J., Zhu, Y.-J., Zhang, Z., Xiao, Z., Chen, Y., Qu, Y., Han, L., & Zhang, H. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00757-5 · Cited by 2
“PDOTS from tumor tissues of patients with melanoma retaining tumor cells, TAMs, monocytes, B and T cells, responded to ICB in microfluidic culture, demonstrating PDOTS profiling as a novel platform for assessing efficacy of ICB in melanoma [31, 32].”
Self-citationTorrisi, R., Giordano, L., Pancetti, S., Carnaghi, C., Basilico, V., Palumbo, R., Gerosa, R., Saltalamacchia, G., Sanò, M. V., Santoro, A., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-40616-1 · Cited by 1
Chen, Y., Xu, N. L. J., Dong, M., Liu, W., Liu, Z., Sun, G., & Jia, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1773734 · Cited by 2
Regulation of the immune CD155–CD226–TIGIT axis by cyclin D-CDK4/6
Fassl, A., Espinoza, M. P., Butter, D., Kołodziejczyk, A., Seehawer, M., Hill, C. N., Ning, X., Branigan, T. B., Peñailillo, J., Saengboonmee, C., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2522872123 · Cited by 1
Self-citationCDK4/6 inhibition enhances CAR-T cell therapy in solid tumors
Lelliott, E. J., Naddaf, J., Lu, K., Cummins, K. D., Ramsbottom, K. M., Reynolds, D. S., Taylor, M., Ambani, K., Munoz, I., Jackson, S., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.024 · Cited by 1
Yang, J., Cheng, C., Luo, W., He, X., Li, Y., Hu, X., Cai, S., Zou, H., Mo, S., & Peng, J. (2026) · MedComm · doi:10.1002/mco2.70741 · Cited by 2
“It was discovered that combinations of CDK4/6 and TBK1/IKKe inhibitors with PD-1 monoclonal antibodies bolstered the antitumor immune response [ 57 ].”
Immune Checkpoint Blockade and Emerging Combination Platforms in Breast Cancer: A Narrative Review
Abbaspour, M., Esmaeil, N., Akbari, V., Ghoreishi, M., & Rafiepoor, H. (2026) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s588323 · Cited by 1
“29 Clinically, combining pembrolizumab with abemaciclib, with or without endocrine therapy, led to interstitial lung disease, liver toxicity, and two deaths in the triplet treatment group.”
4-Hydroxychalcone Exert the Anti-cancer Potential in Colorectal Cancer Through Targeting CDK6
Yang, C., Huangfu, M., Dai, X., Liu, L., Zhao, H., Yuan, Y., Zhang, C., He, T., Shan, C., Wang, X., et al. (2026) · Biological Procedures Online · doi:10.1186/s12575-026-00342-4 · Cited by 1
“Given that the majority of cancer cells possess intact RB1 genes and depend on CDK4/6 activity for sustained proliferation, inhibiting CDK4/6 with drugs has emerged as a promising therapeutic target in oncology [22].”
Tokat, Ü. M., Bilgiç, Ş. N., Adibi, A., Aydın, E., Tutar, O., Cansız, H., Altay, A. Y., Babacan, N., Özgü, E., Manea, A. M., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1858358 · Cited by 1
Zhou, D., Ran, B., Kong, L., Liu, Y., Xiao, L., Chen, X., Liu, W. T., Li, X., Zhang, J. H., Zhang, J., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1839684 · Cited by 1
CDK4/6 Inhibitor-Induced Senescence in Cancer: Mechanisms and Therapeutic Implications
Türker, S. E., Demaria, M., & Wang, B. (2026) · Cancers · doi:10.3390/cancers18142192 · Cited by 1
“Building on these immune-modulatory effects such as enhanced antigen presentation, Treg suppression, and paradoxical PD-L1 upregulation, the combination of CDK4/6 inhibitors with immune checkpoint inhibitors represents a mechanistically grounded strategy [76,128,129].”
Decoding drug resistance and apoptosis in biliary tract cancers using 3D tumor models
Gill, G. S., Sahoo, O. S., Nayek, A., Sarkar, S. K., Kurdia, K. C., Bhardwaj, N., Das, C. J., Galodha, S., Goyal, G., Karmakar, S., et al. (2026) · Frontiers in Cell Death · doi:10.3389/fceld.2026.1819303 · Cited by 1
Mezi, S., Persechino, F., Ascione, A., Chiavassa, A., Artemi, A., Capasso, C., Amato, S., Paganelli, A., & Pellacani, G. (2026) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1603a6849 · Cited by 1
Cao, Y. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1843646 · Cited by 1
“…tumor cell cytotoxicity (Zhou et al., 2020); Inhibition of CDK4/ 6 enhances T cell activation as a result of de-repression of NFAT family proteins (Deng et al., 2018b); beta-catenin represses CCL4 transcription, thus inhibiting anti-cancer immunity (Spranger et al., 2015); HDAC1 brakes…”
CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities
Chinea, L. E., Hauer, C., Pal, K., Chang, H. L., & Chan, I. S. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01232-1 · Cited by 1
Non-canonical approaches to targeting hypoxic tumors.
Zhao, S., & El‐Deiry, W. S. (2022) · PubMed · Cited by 1
CDK Dysregulation in Breast Cancer: A Bioinformatics Analysis
Mir, M. A., Sofi, S., & Ishfaq, P. M. (2023) · Springer eBooks · doi:10.1007/978-981-19-8911-7_8 · Cited by 1
The Dance Between Tumor Molecular Biology and Antitumor Immune Response
Margolin, K. A. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2642 · Cited by 1
Organ-on-chip-based disease models
Fernández‐Costa, J. M., Chiara, F. D., & Ramón‐Azcón, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15384-6.00005-7 · Cited by 1
Organs-on-a-chip in precision medicine
Gupta, V., Sharma, R., Bansal, R., Kaur, G., Kumar, S., & Bansal, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13782-2.00019-x · Cited by 1
Wolff, A., Krone, P., Maennicke, J., Henne, J., Oehmcke-Hecht, S., Redwanz, C., Bergmann‐Ewert, W., Junghanß, C., Henze, L., & Maletzki, C. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102053 · Cited by 1
Yan, S., Zhang, Z., Ji, J., Imam, M., & Wang, S. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189390 · Cited by 1
Tcyganov, E. N., Kwak, T., Yang, X., Poli, A. N. R., Hart, C., Bhuniya, A., Cassel, J. A., Kossenkov, A. V., Auslander, N., Lu, L. S., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0440 · Cited by 4
Gao, Y., He, Y., Wang, C., Zuo, R., Tian, X., Zuo, D., Luo, Y., Liu, W., Feng, Y., Ling, A., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102434 · Cited by 1
“29 CDK4/6i plays an important immunoregulatory role, including enhancing antigen presentation via type III IFN induction, 31 favoring memory T cell formation, 32 and stimulating NFAT activity to promote T cell activation, 72 thereby re-shaping the TME.”
Duso, B. A., Ferraro, E., Mazzarella, L., Jeremias, C. D., & Curigliano, G. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1604136 · Cited by 1
“Also, as previously stated, there is substantial preclinical data supporting a role for CDK4/ 6i in promoting an anti-tumor immune response through enhancement of interferon production by tumor cells [33,74].”
Backgroundde Oliveira, R. V. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.94462 · Cited by 1
A novel immune signature to predict the prognosis of patients with hepatocellular carcinoma
Li, Q., Fan, B., Ding, J., Xiang, X., & Zhang, J. (2021) · Medicine · doi:10.1097/md.0000000000026948 · Cited by 1
“Inhibition of CDK4/6 could augment antitumor immunity by promoting T-cell activation([24]); and, the selective CDK4/6 inhibitor palbociclib has shown encouraging results in preclinical models of HCC.”
BackgroundTowards a scaled-up T cell-mediated cytotoxicity assay in 3D cell culture using microscopyPreprint
Gottschalk, E. Y., Czech, E., Aksoy, B. A., Aksoy, P., & Hammerbacher, J. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/842039 · Cited by 1
“Recently, 3D cell culture systems have been explored in immunotherapy research, with studies using material from patient or mouse tumors to generate spheroids that retain tumor architecture (Jenkins et al. 2018; Deng et al. 2018; Pavesi et al. 2017; Courau et al. 2019).”
BackgroundZhao, S., Zhou, L., Dicker, D. T., Lev, A., Zhang, S., & El‐Deiry, W. S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.20.347633 · Cited by 1
How can we create precision immunotherapy as standard in breast cancer?
Hartman, Z. C. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1951241 · Cited by 1
“While the clinical impact of anti-endocrine drugs and CDK4/6 inhibition on immunity is largely unknown, preclinical studies have suggested the ability of these treatments to stimulate immunity [10,11].”
BackgroundDUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancersPreprint
Pineda, J. M. B., & Bradley, R. K. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.10.548412 · Cited by 1
“…in reduced ICI efficacy, and combination treatment with a MAPK/CDK inhibitor improves response to checkpoint blockade (Ascierto et al., 2019; Deng et al., 2018; Ebert et al., 2016; Goel et al., 2017; Jerby-Arnon et al., 2018; Ribas et al., 2019; Schaer et al., 2018; Sullivan et al., 2019).”
BackgroundDUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancersPreprint
Pineda, J. M. B., & Bradley, R. K. (2023) · eLife · doi:10.7554/elife.89017.1 · Cited by 1
Creason, A., Egger, J., Watson, C., Sivagnanam, S., Chin, K., MacPherson, K., Lin, J., Chen, Y., Johnson, B., Feiler, H. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.27.557464 · Cited by 1
“Immunotherapies that block PD-1/PD-L1 checkpoint activity may dampen immune evasion by the tumor while on CDK4/6i therapy, and, indeed, prior evidence that CDK4/6i primes tumors to respond to PD-1/PD-L1 inhibitors (Deng et al. 2018).”
ResultLewis, D. A., Kar, A., Savage, A. R., Kelly, V., Wright, D., Zamoyska, R., & Ly, T. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.28.640744 · Cited by 1
Differentiation status determines tumorigenicity and immunogenicity of cancer cellsPreprint
Liu, Y., Wang, C., Li, H., & Cao, Y. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.30.656250 · Cited by 1
Andrieu, N., & Bendriss‐Vermare, N. (2018) · HAL · doi:10.1051/medsci/2018217
Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma
Chandra, S., McArthur, G., & Sosman, J. (2019) · Cutaneous Melanoma · doi:10.1007/978-3-319-46029-1_55-1
Anticancer innovative therapy: Highlights from the ninth annual meeting
Volpari, T., Santis, F. D., Bracken, A. P., Pupa, S. M., Buschbeck, M., Wegner, A., Cosimo, S. D., Lisanti, M. P., Dotti, G., Massaia, M., et al. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.12.002
Birth and death of cellular senescence
Wang, B. (2020) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.131223530
Thavaneswaran, S., Sebastian, L. T., Kansara, M., Ballinger, M. L., Espinoza, D., Lin, F., Lee, C. K., Sjoquist, K. M., Grady, J. P., Cowley, M. J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-254137/v1
“In this particular instance, the signals of immune activation provide further supportive rationale for tumor priming with CDK4/6 inhibition, followed by immune checkpoint blockade to increase the likelihood of an effective anti-tumor immune response (15, 16, 18).”
BackgroundCurrent Progress in Cancer Immunotherapies Using Small Molecules Targeting PD-L1 Stability
Leung, M., Pipchuk, A., & Yang, X. (2021) · OBM Genetics · doi:10.21926/obm.genet.2101127
“trials to enhance the response to immune checkpoint blockade [39, 40].”
BackgroundSaavedra, C., Vallejo, A., Longo, F., Domingo, J. J. S., Fernández, M., Gión, M., López-Miranda, E., Martínez-Jáñez, N., Guerra, E., Chamorro, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-798329/v1
“Preclinical studies showed that CDKi boost effector T-cell functions, and their combination with anti-PD-1 antibodies have synergic effect, increasing interferon production in CD8-T-cells and IL-2 in CD4-T-cells [15,16].”
BackgroundWhat's New in Molecular Targeted Therapies for Head and Neck Cancer?
Lee, S.-Y., & Kim, H. R. (2021) · 대한두경부종양학회지 · doi:10.21593/kjhno/2021.37.2.11
Cyclin-Dependent Kinases as Therapeutic Targets
Law, M. E., & Law, B. K. (2021) · Springer eBooks · doi:10.1007/978-3-030-57401-7_10043
Roh, W., Geffen, Y., Miller, M. L., Anand, S. K., Kim, J., Heiman, D. I., Gainor, J. F., Laird, P. W., Cherniack, A. D., & Getz, G. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.20.481157
Rahman, M. H., Hossain, M. A., Ahsan, A., Hasan, I., Sohel, M., Khan, A. A., & Miah, M. S. (2022) · Research Square · doi:10.21203/rs.3.rs-1373879/v1
Alamoudi, M. K., Chipman, M. E., Deieso-Frechette, F., Bogis, A. M., Alqurashi, R. S., Li, K., Zhang, R., Castañer, M., Triafallou, G., Herbosa, C. G., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.25.485706
“Similar phenotypes to our CHA1 studies here were triggered by very diverse signals- including DNMT1 inhibitors, CDK4/6 inhibitors (42, 43, 130), CDK9 inhibitors, LSD1 inhibitors or LINE regulation.”
BackgroundMolecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma
Chandra, S., McArthur, G. A., & Sosman, J. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_55
Congrès de l’association américaine de recherche contre le cancer — AACR 2018
Assoun, S., Benderra, M., Géraud, A., Bayle, A., Boilève, A., Soares, D. G., & Lotz, J. (2018) · ONCOLOGIE · doi:10.3166/onco-2018-0011
Nghiem, P., Pulliam, T., & Lee, J. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734323393.793556922
Cyclin-dependent kinases as therapeutic targets
Law, M. E., & Law, B. K. (2021) · Springer eBooks · doi:10.1007/978-3-030-21573-6_10043-1
Saavedra, C., Vallejo, A., Longo, F., Domingo, J. J. S., Fernández-Abad, M., Gión, M., López-Miranda, E., Martínez-Jáñez, N., Guerra, E., Chamorro, J., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1862721/v1
Saavedra, C., Vallejo, A., Longo, F., Domingo, J. J. S., Fernández-Abad, M., Gión, M., López-Miranda, E., Martínez-Jáñez, N., Guerra, E. M., Chamorro, J., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1862721/v2
Preclinical Cancer Models for the Evaluation of Immunotherapies: From Cell Lines to Animal Models
Pezeshki, P. S., & Rezaei, N. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_206-1
Subhan, M. A. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_136
Roh, W., Geffen, Y., Cha, H., Miller, M. L., Anand, S. K., Kim, J., Heiman, D. I., Gainor, J. F., Laird, P. W., Cherniack, A. D., et al. (2023) · doi:10.1158/0008-5472.c.6514175
Patnaik, A., Yap, T. A., Chung, H. C., Miguel, M. J. D., Bang, Y., Lin, C., Su, W., Italiano, A., Chow, K. H., Szpurka, A. M., et al. (2023) · doi:10.1158/1078-0432.c.6529953
Davis, A. A., Luo, J. R., Zheng, T., Dai, C., Dong, X., Tan, L., Suresh, R., Ademuyiwa, F. O., Rigden, C. E., Rearden, T. P., et al. (2023) · doi:10.1158/1078-0432.c.6533108.v1
Lelliott, E. J., Mangiola, S., Ramsbottom, K. M., Zethoven, M., Lim, L., Lau, P. K. H., Oliver, A. J., Martelotto, L. G., Kirby, L., Martin, C., et al. (2023) · doi:10.1158/2326-6066.c.6550431
Davis, A. A., Luo, J. R., Zheng, T., Dai, C., Dong, X., Tan, L., Suresh, R., Ademuyiwa, F. O., Rigden, C. E., Rearden, T. P., et al. (2023) · doi:10.1158/1078-0432.c.6533108.v2
Goryainova, А. Y., Stukan, А. I., Lymar, Е. V., Викторович, Ш. С., Murashko, R. A., & Andreev, D. V. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-4s-25-32
Feng, C., Li, Y., Zang, M., Jin-si-han, E.-E.-M.-B.-K., He, M., & Lu, Z. (2023) · Medical Science Monitor · doi:10.12659/msm.940556
乌尔肯, ·. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13112580
Song, F., & Chen, Z. (2023) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v31.i24.989
Immune-Checkpoint Inhibitors: A New Line of Attack in Triple-Negative Breast Cancer
Jarroudi, O. A., Bairi, K. E., Curigliano, G., & Afqir, S. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-33602-7_2
Liang, J., Sun, G., Pan, X., Zhang, M., Shen, P., Zhu, S., Zhao, J., Zheng, L., Zhao, J., Chen, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22735563
Liang, J., Sun, G., Pan, X., Zhang, M., Shen, P., Zhu, S., Zhao, J., Zheng, L., Zhao, J., Chen, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22735554
Liu, G., Li, H., Ji, W., Gong, H., Jiang, Y. J., Ji, G., & Liu, G. (2021) · Figshare · doi:10.6084/m9.figshare.16756006
Liu, G., Li, H., Ji, W., Gong, H., Jiang, Y. J., Ji, G., & Liu, G. (2021) · Figshare · doi:10.6084/m9.figshare.16755997
Liu, G., Li, H., Ji, W., Gong, H., Jiang, Y. J., Ji, G., & Liu, G. (2021) · Figshare · doi:10.6084/m9.figshare.16755991
Liu, G., Li, H., Ji, W., Gong, H., Jiang, Y., Ji, G., & Liu, G. (2021) · Figshare · doi:10.6084/m9.figshare.16755994
Liu, G., Li, H., Ji, W., Gong, H., Jiang, Y. J., Ji, G., & Liu, G. (2021) · Figshare · doi:10.6084/m9.figshare.16756009
Liu, G., Li, H., Ji, W., Gong, H., Jiang, Y., Ji, G., & Liu, G. (2021) · Figshare · doi:10.6084/m9.figshare.16756003
Liu, G., Li, H., Ji, W., Gong, H., Jiang, Y. J., Ji, G., & Liu, G. (2021) · Figshare · doi:10.6084/m9.figshare.16756000
DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancersPreprint
Pineda, J. M. B., & Bradley, R. K. (2024) · eLife · doi:10.7554/elife.89017.2
Lambrechts, Y., Hatse, S., Kenis, C., Decoster, L., de Azambuja, E., de Azambuja, E., Quaghebeur, C., Quaghebeur, C., Cornélis, F., Verhoeven, D., et al. (2024) · Ageing and Cancer Research & Treatment · doi:10.37155/2972-4759-2024-02-01-3 · Cited by 1
Barroso‐Sousa, R., Weis, L. N., & Tolaney, S. M. (2024) · Cancer immunotherapy · doi:10.1007/13905_2024_40
Scafetta, R., Carnevale, A., Castellano, G., Giugliano, F., Santoro, C., Scalia, R., Trapani, D., & Curigliano, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13376-3.00008-3
Yuan, K., Chen, W., Wang, X., & Yang, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00022-4
Targeting CDK4 and CDK6 in hormone-dependent cancers
Bobbitt, J. R., & Keri, R. A. (2024) · Vitamins and hormones · doi:10.1016/bs.vh.2024.10.006
Desai, K. K., Tiburcio, P. D. B., Warne, A., Nabbi, A., Zhou, S., Reiff, S. D., Campbell, M. E., & Chen, K. S.-M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.29.626084
Immune Gene Signature as a Predictor of CDK4/6 Inhibitor Response in HR+/HER2– Breast CancerPreprint
Felip, E., García-Vidal, E., Heras, S. C. L., Bernat‐Peguera, A., Cirauqui, B., Bergamino, M. A., Quiroga, V., Teruel, I., Ferrando‐Díez, A., Pous, A., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6129690/v1
Ma, J., Wang, Y., Wu, Z., Zhou, L., Lin, Y., Xu, S., Zhang, J., Lu, J., & Yin, W. (2025) · iScience · doi:10.1016/j.isci.2025.112620
“41,42 Preclinical studies also found that CDKI combined with immune check-point inhibitors could further downregulate cell cycle genes and increase immune memory of tumor cells through Rb protein, 42 exhibiting synergistic anti-tumor effect.”
Zhang, F., Boutin, L., Das, I., Melief, J., Singh, M., Stantic, M., Zhang, L., Alzrigat, M., Azimi, A., Baldran-Groves, L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.04.663080
Identifying potential therapeutic targets for prostate cancer with mediating role in tumor immunity
Wu, Z., Li, S., Li, Y., Wang, Z., & Wang, W. (2025) · Discover Oncology · doi:10.1007/s12672-025-02985-3 · Cited by 1
“For instance, combining CDK4/6 inhibitors with immune checkpoint inhibitors is proved to enhance immune responses and increase lymphocyte infiltration within the tumor in prostate cancer treatment [16, 17].”
Self-citationCDK4/6 inhibitors for the treatment of breast cancer
Ayush, S., Snehal, P., Singh, R. M., & Kumar, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33653-9.00008-9
Preclinical Cancer Models for the Evaluation of Immunotherapies: From Cell Lines to Animal Models
Pezeshki, P. S., & Rezaei, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00767-4_206
Chen, J., He, J., Xu, X., Sun, H., & Zhang, J. (2025) · PLoS ONE · doi:10.1371/journal.pone.0333916
Metadata
- Authors
- Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., Ivanova, E., Paweletz, C. P., Bowden, M., Zhou, C. W., Herter-Sprie, G. S., Sorrentino, J. A., Bisi, J. E., Lizotte, P. H., Merlino, A. A., Quinn, M. M., Bufe, L. E., Yang, A., Zhang, Y., Zhang, H., Gao, P., Chen, T., Cavanaugh, M. E., Rode, A. J., Haines, E., Roberts, P. J., Strum, J. C., Richards, W. G., Lorch, J. H., Parangi, S., Gunda, V., Boland, G. M., Bueno, R., Palakurthi, S., Freeman, G. J., Ritz, J., Haining, W. N., Sharpless, N. E., Arthanari, H., Shapiro, G. I., Barbie, D. A., Gray, N. S., & Wong, K.-K.
- Affiliations
- NYU Langone Health (US)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- 9G1 Therapeutics, Research Triangle Park, North Carolina.
- Brigham and Women's Hospital (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Barbie, David A.
- Gray, Nathanael S.
- Wong, Kwok-Kin
- ORCID
- Deng, Jiehui
- Wang, Eric S.
- Jenkins, Russell W.
- Li, Shuai
- Dries, Ruben
- Yates, Kathleen
- Chhabra, Sandeep
- Huang, Wei
- Liu, Hongye
- Aref, Amir R.
- Ivanova, Elena
- Paweletz, Cloud P.
- Bowden, Michaela
- Zhou, Chensheng W.
- Herter-Sprie, Grit S.
- Sorrentino, Jessica A.
- Bisi, John E.
- Lizotte, Patrick H.
- Yang, Annan
- Zhang, Hua
- Gao, Peng
- Chen, Ting
- Haines, Eric
- Roberts, Patrick J.
- Strum, Jay C.
- Richards, William G.
- Lorch, Jochen H.
- Parangi, Sareh
- Boland, Genevieve M.
- Bueno, Raphael
- Palakurthi, Sangeetha
- Freeman, Gordon J.
- Ritz, Jerome
- Haining, W. Nicholas
- Sharpless, Norman E.
- Arthanari, Haribabu
- Shapiro, Geoffrey I.
- Barbie, David A.
- Gray, Nathanael S.
- Wong, Kwok-Kin
- Venue
- Cancer Discovery
- Published
- 2018-02-01
- Volume
- 8
- Issue
- 2
- Pages
- 216-233
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5809273
- OpenAlex
- W2766016994
- Cited by
- 770
- References
- 63
- Citations by year
- 2026: 62 · 2025: 111 · 2024: 83 · 2023: 109 · 2022: 115 · 2021: 104 · 2020: 96 · 2019: 61 · 2018: 29
- FWCI
- 22.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Damon Runyon Cancer Research Foundation (Damon Runyon) (DRG-2270-16)
- HHS | NIH | National Cancer Institute (NCI) (CA154303-05, CA179483-03, P01CA120964, 5R01CA163896-04, 5R01CA140594-07, 5R01CA122794-10, 5R01CA166480-04)
- Dana-Farber Cancer Institute (DFCI) (Medical Oncology Discovery Grant)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- CDK4/6 inhibitors, antitumor immunity, T cell activation, anti-PD-1 therapy, immune checkpoint blockade, combination immunotherapy, tumor-infiltrating T cells, small-molecule immunomodulators
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Antineoplastic Agents, Humans, Lymphocyte Activation, Neoplasms, T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
